Intervention
Berzosertib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
9 shownA Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsNCT04826341 · 2021-09-20
COMPLETEDLurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersNCT04802174 · 2021-06-01
ACTIVE_NOT_RECRUITINGTesting the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung CancerNCT04216316 · 2021-04-14
ACTIVE_NOT_RECRUITINGBerzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)NCT04768296 · 2021-03-29
COMPLETEDTesting the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerNCT04052555 · 2020-09-24
ACTIVE_NOT_RECRUITINGRandomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the LungsNCT03896503 · 2019-12-30
ACTIVE_NOT_RECRUITINGM6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate CancerNCT03517969 · 2019-05-29
ACTIVE_NOT_RECRUITINGTesting the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsNCT02589522 · 2017-05-22
ACTIVE_NOT_RECRUITINGM6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02595931 · 2016-07-22
ACTIVE_NOT_RECRUITINGCommon conditions
Stage IV Lung Cancer AJCC v83Metastatic Lung Small Cell Carcinoma2SCLC2Advanced Solid Tumor1Advanced Solid Tumors1Bilateral Breast Carcinoma1Castration-Resistant Prostate Carcinoma1Extensive Stage Lung Small Cell Carcinoma1Extrapulmonary Small Cell Neuroendocrine Carcinoma1HER2-Negative Breast Carcinoma1High Grade Neuroendocrine Cancers1HRD Cancer1Limited Stage Lung Small Cell Carcinoma1Localized Breast Carcinoma1Lung Non-Small Cell Squamous Carcinoma1Metastatic Colorectal Carcinoma1Metastatic Lung Neuroendocrine Neoplasm1Metastatic Lung Non-Small Cell Carcinoma1Metastatic Malignant Neoplasm in the Brain1Metastatic Malignant Solid Neoplasm1Metastatic Pancreatic Carcinoma1Metastatic Prostate Carcinoma1Platinum-Resistant Lung Small Cell Carcinoma1Platinum-Sensitive Lung Small Cell Carcinoma1Recurrent Breast Carcinoma1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING7
COMPLETED2
Phase mix
PHASE16
PHASE26
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.